Concepedia

Matthieu Klopfenstein

MK

Statistics

Publications

3

Citations

270

H-Index

3

Active since

2009

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Matthieu Klopfenstein is an author at Novartis (Switzerland) specializing in pharmacotherapy, radiation oncology, and cancer therapeutics.

Top concepts

Publications per year

2009–2022

3

Publications

3

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

Madlaina Breuleux, Matthieu Klopfenstein, Christine Stephan et al. · Molecular Cancer Therapeutics · 2009 · 240 citations · Full text

PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

Haihui Lu, Adwait Oka, Michelle Coulson et al. · Blood · 2022 · 19 citations

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced <i>TP53</i> wt acute leukemias

Eytan M. Stein, Jöerg Chromik, Daniel J. DeAngelo et al. · Cancer Research · 2017 · 11 citations

, , +17

Rows per page

1–3 of 3